-
May 9, 2019Shares of the combined company to commence trading on the NYSE American exchange under the new symbol "ARMP" on May 10, 2019
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections,...
-
May 8, 2019
AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for...
-
Apr 2, 2019C3J’s pending merger with AmpliPhi Biosciences, which will create a clinical-stage phage leader, is on track to close in May 2019
LOS ANGELES, Calif., April 2, 2019 — C3J Therapeutics, Inc. (C3J) a private clinical stage biotechnology company focused on the development of novel targeted antimicrobials based on...
-
Jan 4, 2019Transaction to result in NYSE American-listed company focused on development of precisely-targeted bacteriophage therapeutics
SAN DIEGO & LOS ANGELES, January 4, 2019 — AmpliPhi Biosciences Corporation (“AmpliPhi”) (NYSE American: APHB), a clinical-stage biotechnology company focused on the development of precisely...
-
Dec 18, 2018AmpliPhi’s wholly owned GMP facility now capable of producing material for over 100,000 doses from each drug substance batch of AB-SA01, sufficient to support clinical trial requirements
SAN DIEGO--(BUSINESS WIRE)--AmpliPhi Biosciences Corporation (NYSE AMERICAN: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for patients...
